secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2024-01-25T23:59:59+00:00
Accession:  0001104659-24-006477
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA delays YUTREPIA PDUFA date; PH-ILD amendment process ongoing
----------------------------------------------------------------

- FDA unable to issue action letter by Jan. 24, 2024 PDUFA date; no new goal date set.
- No additional clinical data requested; FDA confirming process to add PH-ILD indication.
- Federal Circuit upheld PTAB invalidity of '793 patent; '327 patent not subject to 30-month stay.
- Company expects final approval after Tyvaso regulatory exclusivity expires March 31, 2024.
- YUTREPIA already has tentative approval for PAH; quality, safety, efficacy standards met.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465924006477/0001104659-24-006477-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465924006477/tm244104d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-006477

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer